Cart
sales@molnova.com
TRH-AMC
CAS No. 190836-86-3
TRH-AMC( ——— )
Catalog No. M40246 CAS No. 190836-86-3
TRH-AMC is a fluorogenic substrate used in a coupled assay for thyrotropin-releasing hormone(TRH)-degrading ectoenzyme.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTRH-AMC
-
NoteResearch use only, not for human use.
-
Brief DescriptionTRH-AMC is a fluorogenic substrate used in a coupled assay for thyrotropin-releasing hormone(TRH)-degrading ectoenzyme.
-
DescriptionTRH-AMC is a fluorogenic substrate used in a coupled assay for thyrotropin-releasing hormone(TRH)-degrading ectoenzyme.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptorothers
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number190836-86-3
-
Formula Weight520.61
-
Molecular FormulaC26H28N8O4
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gaia A Scalabrino, et al. Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone. Neuropharmacology. 2007 Jun;52(7):1472-81.?
molnova catalog
related products
-
L-BUTHIONINE-(SR)-SU...
L-Buthionine-(SR)-sulfoximine is a cell-permeable and irreversible inhibitor of γ-glutamylcysteine synthetase (Ki <100 μM) that induces oxidative stress in cells by depleting GSH.
-
CEF19,Epstein-Barr V...
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain).
-
(1R,2R)-ML-SI3
(1R,2R)-ML-SI3 ((-)-trans-ML-SI3) is a selective TRPML1, TRPML2, and TRPML3 inhibitor for the study of neurodegenerative and cardiovascular diseases.
